Encision Inc. reports company developments tied to its medical-device business and the trading status of its common stock. The company designs and markets surgical instrumentation for minimally invasive procedures and owns patented Active Electrode Monitoring (AEM®) technology, which is designed to prevent stray energy burns during surgery.
Recurring updates include quarterly and annual financial results, product and service revenue trends, operating-expense restructuring, common-stock financing, governance changes, and the company’s Form 15 deregistration process. News also covers Encision’s response to procedure migration toward robotic surgery and its development work in surgical safety devices, including activity in the ear, nose and throat market.
Encision Inc. (ECIA) reported its fiscal 2025 third quarter results ending December 31, 2024. The company posted total net revenue of $1.59 million, comprising $1.46 million in product revenue and $128,000 in service revenue, with a quarterly net loss of $24,000 or $(0.00) per diluted share.
For the nine-month period, total net revenue was $4.97 million with a net loss of $172,900 or $(0.01) per diluted share. Gross margin on product revenue improved to 54% in Q3 FY2025 from 46% in Q3 FY2024. The company is developing a new product for ENT surgery, expected to launch in the first half of FY2026.
The quarter was described as a rebuilding period, with new sales partners onboarded and internal cost reduction measures implemented, expected to show effects from Q4 onwards.
Encision Inc. (OTC PINK:ECIA) reported financial results for Q2 FY2025 ending September 30, 2024. Total net revenue was $1.75 million, down from $1.83 million in Q2 FY2024, with a quarterly net loss of $170,000 ($(0.01) per share). Product net revenue decreased to $1.65 million from $1.75 million year-over-year, while service revenue increased to $101,000. The company maintained a 47% gross margin on product revenue. For the six-month period, total revenue was $3.39 million with a net loss of $148,000. Performance was impacted by reduced surgical procedures due to hurricanes in the southeast and saline availability issues. The company plans to launch a new ENT market product in early FY2026.
Encision Inc. (OTC PINK:ECIA), a medical device company specializing in Active Electrode Monitoring (AEM) Technology, has signed a Master Services Agreement with Vicarious Surgical Inc. The agreement, effective July 8, 2024, involves Encision providing design services for elements of Vicarious' robotic surgical system.
Gregory J. Trudel, President and CEO of Encision, expressed excitement about the collaboration, highlighting the opportunity to bring best-in-class technology to surgical robotics and contribute to patient safety and clinical performance. Encision, based in Boulder, Colorado, focuses on developing surgical instrumentation that enhances patient safety and surgical performance across various minimally invasive procedures.
Encision Inc. (OTC PINK:ECIA), a medical device company specializing in Active Electrode Monitoring (AEM) Technology, reported financial results for its fiscal 2025 first quarter ended June 30, 2024. The company achieved:
- Total net revenue of $1.63 million
- Quarterly net income of $22,000 ($0.00 per diluted share)
- Product net revenue of $1.59 million
- Service net revenue of $39,000
- Gross margin on product net revenue increased to 58% from 52% in the previous year
The improved performance is attributed to higher operating efficiencies and increased selling prices. CEO Gregory Trudel highlighted the company's progress in sales channel investment and technology development, as well as efforts to create new service revenue streams.
Encision Inc. (OTCPK:ECIA), a medical device company specializing in Active Electrode Monitoring (AEM) Technology, reported its fiscal 2024 fourth quarter and full-year results. Key points:
- Q4 net revenue: $1.53 million, down from $1.81 million year-over-year
- Q4 net loss: $409,000 or $(0.03) per diluted share
- Full-year net revenue: $6.59 million, down from $7.35 million in fiscal 2023
- Full-year net loss: $692,000 or $(0.06) per diluted share
- Gross margin decreased to 42% in Q4 and 48% for the full year
The company faced challenges due to COVID-19 impacts and market changes but remains optimistic about fiscal 2025 with a strengthening sales channel and new product introduction.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Encision Inc. (OTC PINK:ECIA) has signed a Supplier Agreement with Human Xtensions, marking a strategic partnership aimed at enhancing robotic surgery performance. Encision will provide manufacturing services, including procurement, assembly, and testing of products tailored to Human X's specifications. This collaboration aims to elevate clinical performance through Encision's innovative Active Electrode Monitoring (AEM) Technology and advanced surgical instruments. Gregory J. Trudel, CEO, expressed enthusiasm for the partnership's potential to set new standards in surgical precision. However, the company acknowledges inherent risks in product development and market acceptance.